<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen52">
		<pathogen_name>Measles virus</pathogen_name>
		<taxon_id>11234</taxon_id>
		<pathogenesis refs="reference724">Measles virus (MV) has two envelope glycoproteins, the haemagglutinin (H) and fusion proteins, which are responsible for attachment and membrane fusion, respectively. Human signalling lymphocyte activation molecule (SLAM; also called CD150), a membrane glycoprotein of the immunoglobulin superfamily, acts as a cellular receptor for MV. SLAM is expressed on immature thymocytes, activated lymphocytes, macrophages and dendritic cells. It regulates production of interleukin (IL)-4 and IL-13 by CD4+ T cells, as well as production of IL-12, tumour necrosis factor alpha and nitric oxide by macrophages. The distribution of SLAM is in accord with the lymphotropism and immunosuppressive nature of MV (Yanagi et al., 2006).</pathogenesis>
		<disease_name>Measles</disease_name>
		<protective_immunity refs="reference723">Although innate responses probably contribute to control of virus replication during the incubation period, the onset of clinically apparent disease coincides with the appearance of MV-specific adaptive humoral and cellular immune responses. Antibody can protect from MV infection and may contribute to recovery from infection. Antibody is sufficient for protection because infants are protected by maternal antibody and passive transfer of immune serum can modify or interfere with measles vaccination and can partially protect children from measles after exposure. The best correlate of protection from infection is the level of neutralizing antibody. In infants, the level of maternal antibody correlates with failure of the humoral response to vaccination (Griffin et al., 2008).</protective_immunity>
		<host_range refs="reference1545">Humans are the only known natural host of measles, although the virus can infect some non-human primate species (Wiki: Measles).</host_range>
		<introduction refs="reference723">Measles virus is a negative strand RNA virus in the Morbillivirus genus of the Paramyxoviridae family. The virus was first isolated in 1954. Measles virus causes measles, a highly infectious disease of humans spread by the respiratory route and characterized by fever and rash. Important complications include secondary infections associated with MV-induced immune suppression and the neurological disease post-infectious encephalomyelitis (Griffin et al., 2008).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine4227">
		<vaccine_name>ALVAC-MV-HA/F</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004741</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3259">Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1743" gene_id="gene578">
			<type>Recombinant vector construction</type>
			<description refs="reference3259">Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1744" gene_id="gene577">
			<type>Recombinant vector construction</type>
			<description refs="reference3259">Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1836" host_id="host36">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3259">Vaccinate the dogs with recombinant vaccine (Taylor et al., 1992).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3259">The recombinants elicited a protective immune response. The level of MV neutralizing antibodies and the level of protection induced against CDV challenge achieved by the host-restricted CPV vector were equivalent to that obtained by vaccinia virus vectors expressing the same MV antigens (Taylor et al., 1992).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3259">Lethal does of canine distember virus (CDV) (Taylor et al., 1992).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine335">
		<vaccine_name>Attenuvax</vaccine_name>
		<proper_name>Measles Virus Vaccine Live</proper_name>
		<brand_name>Attenuvax</brand_name>
		<manufacturer>Merck &amp; Co., Inc, USA License #0002</manufacturer>
		<vo_id>VO_0000007</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed>USA (License #0002)</location_licensed>
		<description refs="">ATTENUVAX is a live virus vaccine for vaccination against measles (rubeola).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">The vaccine must be maintained at a temperature of 10°C (50°F) or colder.</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference722">ATTENUVAX is a sterile lyophilized preparation of a more attenuated line of measles virus derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture (FDA: Attenuvax).</preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs="">A more attenuated line of measles virus derived from Enders' attenuated Edmonston strain</antigen>
		<host_response host_response_id="host_response427" host_id="host2">
			<immune_response refs="reference722">A single injection of the vaccine has been shown to induce measles hemagglutination-inhibition (HI) antibodies in 97% or more of susceptible persons (FDA: Attenuvax).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="">Side effects of vaccination include: fever, headache. dizziness, redness, soreness and swelling at the injection site.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1607">
		<vaccine_name>Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Modified Live Virus Vaccine (USDA: 1341.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Pfizer, Inc.</manufacturer>
		<vo_id>VO_0002095</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1686">
		<vaccine_name>Canine Distemper-Measles Modified Live Virus Vaccine (USDA: 1351.20)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer>Pfizer, Inc.</manufacturer>
		<vo_id>VO_0002096</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA</location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine568">
		<vaccine_name>Eolarix</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Eolarix</brand_name>
		<manufacturer>GlaxoSmithKline</manufacturer>
		<vo_id>VO_0010712</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Human albumin, Lactose, Dextran.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">2 to 8°C (36 to 46°F) or colder. Do not freeze.</storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine601">
		<vaccine_name>M-M-R II</vaccine_name>
		<proper_name></proper_name>
		<brand_name>M-M-R II</brand_name>
		<manufacturer>Merck Frosst</manufacturer>
		<vo_id>VO_0000069</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Bovine serum, Glutamate, Yeast-derived, recombinant Human albumin, Residual protein, from cell culture, Sorbitol, Sucrose.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1068">
		<vaccine_name>Measles Virus vaccine VEE/SIN-H</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004187</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Licensed</status>
		<vector>Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles [Ref1175:Pan et al., 2010].</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering555" gene_id="gene577">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response825" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Rhesus macaques</host_strain>
			<vaccination_protocol refs="reference1175">Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 10^8 VEE/SIN-H particles or 108 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010)</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1175">Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1175">For MV challenge, 10^4 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine976">
		<vaccine_name>Measles Virus vaccine VEE/SIN-H+F</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011422</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles [Ref1175:Pan et al., 2010].</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering459" gene_id="gene578">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering460" gene_id="gene577">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response731" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Rhesus macaques</host_strain>
			<vaccination_protocol refs="reference1175">Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 10^8 VEE/SIN-H particles or 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys  were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1175">Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1175">For MV challenge, 10^4 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010).</challenge_protocol>
			<description refs=""></description>
              <host_gene_response host_gene_response_id="host_gene_response281" gene_id="gene1200">
			    <description refs="reference1175">VEE/SIN-H+F vaccinated rhesus macaques showed a significant increase in IFN-gamma producing cells in blood 1 to 2 weeks after vaccination as compared to the current live attenuated virus vaccine (LAV). The significant increase came after stimulation with the measles H-peptide (Pan et al., 2010).</description>
			  </host_gene_response>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine980">
		<vaccine_name>Measles Virus Vaccine VVM</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011537</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia Virus [Ref1177:Brinckmann et al., 1991].</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering464" gene_id="gene581">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response735" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Lewis</host_strain>
			<vaccination_protocol refs="reference1177">To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1177">Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1177">Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10^4 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine978">
		<vaccine_name>Measles Virus Vaccine VVN</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011535</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia virus [Ref1177:Brinckmann et al., 1991].</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering462" gene_id="gene579">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response733" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Lewis</host_strain>
			<vaccination_protocol refs="reference1177">To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three
times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1177">Rats immunized with recombinant VVN survived a MV challenge infection (Brinckmann et al., 1991).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1177">Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH  (0.5 × 10^4 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine979">
		<vaccine_name>Measles Virus Vaccine VVP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011536</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia virus [Ref1177:Brinckmann et al., 1991].</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering463" gene_id="gene580">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response734" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Lewis</host_strain>
			<vaccination_protocol refs="reference1177">To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1177">Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1177">Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10^4 to 8 x 10 ~ TCID50)  (Brinckmann et al., 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine616">
		<vaccine_name>Priorix</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Priorix</brand_name>
		<manufacturer>GlaxoSmithKline</manufacturer>
		<vo_id>VO_0010734</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Lactose.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">Store at at 2 to 8°C.</storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine619">
		<vaccine_name>Priorix-Tetra</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Priorix-Tetra</brand_name>
		<manufacturer>GlaxoSmithKline</manufacturer>
		<vo_id>VO_0010735</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Lactose.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="reference925">Store at at 2 to 8°C. Do not freeze (GSK: Priorix-Tetra).</storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine378">
		<vaccine_name>ProQuad</vaccine_name>
		<proper_name>Measles, Mumps, Rubella and Varicella Virus Vaccine Live</proper_name>
		<brand_name>ProQuad</brand_name>
		<manufacturer>Merck &amp; Co, Inc.</manufacturer>
		<vo_id>VO_0000091</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>USA (License #0002)</location_licensed>
		<description refs="reference796">ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R*II (Measles, Mumps and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck) refrigerator-stable formulation, the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells (FDA: ProQuad).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">maintained at a temperature of 2° to 8°C (36° to 46°F) or colder.</storage>
		<virulence refs=""></virulence>
		<preparation refs="">propagated in chick embryo cell culture.</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response472" host_id="host2">
			<immune_response refs="reference796">According to clinical trials, there were high levels of antibodies in 98.9% of those vaccinated after a single dose of Proquad (FDA: ProQuad).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="">Side effects of vaccination include: injection site reactions, fever, irritability and diarrhea.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene578">
        <gene_name>F fusion protein</gene_name>
        <strain>Measles morbillivirus</strain>
        <vo_id>VO_0011167</vo_id>
        <ncbi_gene_id>1489800</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9626950</ncbi_protein_id>
        <gene_locus_tag>MeVgp4</gene_locus_tag>
        <gene_refseq>AB016162</gene_refseq>
        <protein_refseq>NP_056922</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11234</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>4875</gene_start>
        <gene_end>7246</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>8.55</protein_pi>
        <protein_weight>55859.92</protein_weight>
        <protein_length>550</protein_length>
        <protein_note>additional G inserted at 2499:V</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001498.1:4875-7246 Measles virus, complete genome
AGGGCCAAGGAACACACACACTCGACAGAACCCAGACCCCGGCCCGCGGCACCGCGCCCCCACCCCCCGA
AAACCAGAGGGAGCCCCCAACCAAACCCGCCGGCCCCCCCGGTGCCCACAGGTAGGCACACCAACCCCCG
ACCAGACCCAGCACCCAGCCACCGACAATCCAAGACGGGGGGCCCCCCCCAAAAAAAGGCCCCCAGGGGC
CGACAGCCAGCATCGCGAGGAAGCACACCCACCCCACACACGACCACGGCAACCGAACCAGAGTCCAGAC
CACCCTGGGCCACCAGCTCCCAGACTCGGCCATCACCCCGCAAAAAGGAAAGGCCACAACCCGCGCACCC
CAGCCCCGATCCGGCGGGCAGCCACTCAACCCGAACCAGCACCCAAGAGCGATCCCTGGGGGACCCCCAA
ACCGCAAAAGACATCAGTATCCCACAGCCTCTCCAAGTCCCCCGGTCTCCTCCTCTTCTCGAAGGGACCA
AAAGATCAATCCACCACATCCGACGACACTCAATTCCCCACCCCCAAAGGAGACACCGGGAATCCCAGAA
TCAAGACTCATCCAGTGTCCATCATGGGTCTCAAGGTGAACGTCTCTGCCATATTCATGGCAGTACTGTT
AACTCTCCAAACACCCACCGGTCAAATCCATTGGGGCAATCTCTCTAAGATAGGGGTGGTAGGGATAGGA
AGTGCAAGCTACAAAGTTATGACTCGTTCCAGCCATCAATCATTGGTCATAAAATTAATGCCCAATATAA
CTCTCCTCAATAACTGCACGAGGGTAGAGATCGCAGAATACAGGAGACTACTGAGAACAGTTTTGGAACC
AATTAGAGATGCACTTAATGCAATGACCCAGAATATAAGACCGGTTCAGAGTGTAGCTTCAAGTAGGAGA
CACAAGAGATTTGCGGGAGTTGTCCTGGCAGGTGCGGCCCTAGGCGTTGCCACAGCTGCTCAGATAACAG
CCGGCATTGCACTTCACCAGTCCATGCTGAACTCTCAAGCCATCGACAATCTGAGAGCAAGCCTGGAAAC
TACTAATCAGGCAATTGAGGCAATCAGACAAGCAGGGCAGGAGATGATATTGGCTGTTCAGGGTGTCCAA
GACTACATCAATAATGAGCTGATACCGTCTATGAACCAACTATCTTGTGATTTAATCGGCCAGAAGCTAG
GGCTCAAATTGCTCAGATACTATACAGAAATCCTGTCATTATTTGGCCCCAGCTTACGGGACCCCATATC
TGCGGAGATATCCATCCAGGCTTTGAGCTATGCGCTTGGAGGAGATATCAATAAGGTATTAGAAAAGCTC
GGATACAGTGGAGGTGATTTACTGGGCATCTTAGAGAGCAGAGGAATAAAGGCCCGGATAACTCACGTCG
ACACAGAGTCCTACTTCATTGTACTCAGTATAGCCTATCCGACGCTGTCCGAGATTAAGGGGGTGATTGT
CCACCGGCTAGAGGGGGTCTCGTACAATATAGGCTCTCAAGAGTGGTATACCACTGTGCCCAAGTATGTT
GCAACCCAAGGGTACCTTATCTCGAATTTTGATGAGTCATCGTGTACTTTCATGCCAGAGGGGACTGTGT
GCAGCCAAAATGCCTTGTACCCGATGAGTCCTCTGCTCCAAGAATGCCTCCGGGGGTCCACCAAGTCCTG
TGCTCGTACACTCGTATCCGGGTCTTTTGGGAACCGGTTCATTTTATCACAAGGGAACCTAATAGCCAAT
TGTGCATCAATCCTCTGCAAGTGTTACACAACAGGAACGATCATTAATCAAGACCCTGACAAGATCCTAA
CATACATTGCTGCCGATCACTGCCCGGTGGTCGAGGTGAACGGTGTGACCATCCAAGTCGGGAGCAGGAG
GTATCCGGACGCGGTGTACCTGCACAGAATTGACCTCGGTCCTCCCATATCATTGGAGAGGTTGGACGTA
GGGACAAATCTGGGGAATGCAATTGCTAAGTTGGAGGATGCCAAGGAATTGTTGGAGTCATCGGACCAGA
TATTGAGGAGTATGAAAGGTTTATCGAGCACTAGCATAGTTTACATCCTGATTGCAGTGTGTCTTGGAGG
GTTGATAGGGATCCCCGCTTTAATATGTTGCTGCAGGGGGCGCTGTAACAAAAAGGGAGAACAAGTTGGT
ATGTCAAGACCAGGCCTAAAGCCTGATCTTACAGGGACATCAAAATCCTATGTAAGGTCGCTCTGATCCT
CTACAACTCTTGAAACACAGATTTCCCACAAGTCTCCTCTTCGTCATCAAGCAACCACCGCATCCAGCAT
CAAGCCCACCTGAAATTGTCTCCGGCTTCCCTCTGGCCGAACGATATCGGTAGTTAATTAAA

</dna_sequence>
        <protein_sequence>>NP_056922.1 fusion protein [Measles morbillivirus]
MGLKVNVSAIFMAVLLTLQTPTGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNITLLNNCTR
VEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVASSRRHKRFAGVVLAGAALGVATAAQITAGIALHQS
MLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPSMNQLSCDLIGQKLGLKLLRYY
TEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSGGDLLGILESRGIKARITHVDTESYFIV
LSIAYPTLSEIKGVIVHRLEGVSYNIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGTVCSQNALYP
MSPLLQECLRGSTKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHC
PVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMKGL
SSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRPGLKPDLTGTSKSYVRSL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice vaccinated with a vaccinia virus recombinant encoding the fusion protein of Measles virus developed measles neutralizing antibodies.  The mice also resisted a normally lethal intracerebral inoculation of a cell-associated measles virus subacute sclerosing panencephalitis strain [Ref1314:Drillien et al., 1988].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene577">
        <gene_name>H hemagglutinin protein</gene_name>
        <strain>Measles morbillivirus</strain>
        <vo_id>VO_0011166</vo_id>
        <ncbi_gene_id>1489801</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9626951</ncbi_protein_id>
        <gene_locus_tag>MeVgp5</gene_locus_tag>
        <gene_refseq>AB016162</gene_refseq>
        <protein_refseq>NP_056923</protein_refseq>
        <pdb_id>2RKC</pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11234</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>7250</gene_start>
        <gene_end>9207</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>7.85</protein_pi>
        <protein_weight>64311.39</protein_weight>
        <protein_length>617</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001498.1:7250-9207 Measles virus, complete genome
TAGGGTGCAAGATCATCCACAATGTCACCACAACGAGACCGAATAAATGCCTTCTACAAAGACAACCCAC
ATCCTAAGGGAAGTAGGATAGTTATTAACAGAGAACATCTTATGATTGATAGACCTTATGTTTTGCTGGC
TGTTCTATTCGTCATGTTTCTGAGCTTGATCGGGTTGCTAGCCATTGCAGGCATTAGACTCCATCGTGCA
GCCATCTACACCGCAGAGATCCATAAGAGCCTCAGCACCAATCTAGATGTAACTAACTCGATCGAGCATC
AGGTCAAGGACGTGCTGACACCACTCTTCAAGATCATTGGTGATGAAGTGGGCCTGAGGACACCTCAGAG
ATTCACTGACCTAGTGAAATTCATCTCTGACAAAATTAAATTCCTTAATCCGGATAGGGAGTACGACTTC
AGAGATCTCACTTGGTGTATCAACCCGCCAGAGAGAATCAAATTGGATTATGATCAATACTGTGCAGATG
TGGCTGCTGAAGAACTCATGAATGCATTGGTGAACTCAACTCTACTGGAGGCCAGGGCAACCAATCAGTT
CCTAGCTGTCTCAAAGGGAAACTGCTCAGGGCCCACTACAATCAGAGGTCAATTCTCAAACATGTCGCTG
TCCCTGTTGGACTTGTATTTAAGTCGAGGTTACAATGTGTCATCTATAGTCACTATGACATCCCAGGGAA
TGTACGGGGGAACTTACCTAGTGGGAAAGCCTAATCTGAGCAGTAAAGGGTCAGAGTTGTCACAACTGAG
CATGCACCGAGTGTTTGAAGTAGGGGTTATCAGAAATCCGGGTTTGGGGGCTCCGGTGTTCCATATGACA
AACTATTTTGAGCAACCAGTCAGTAATGATTTCAGCAACTGCATGGTGGCTTTGGGGGAGCTTAAATTCG
CAGCCCTCTGTCACAGGGAAGATTCTATCACAATTCCCTATCAGGGGTCAGGGAAAGGTGTCAGCTTCCA
GCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGACATGCGATCCTGGGTCCCCCTATCAACGGATGAT
CCAGTGATAGATAGGCTTTACCTCTCATCTCACAGAGGTGTTATCGCTGACAATCAAGCAAAATGGGCTG
TCCCGACAACACGGACAGATGACAAGTTGCGAATGGAGACATGCTTCCAGCAGGCGTGTAAGGGTAAAAA
CCAAGCACTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAACAGGATTCCTTCATACGGGGTCTTG
TCTGTTAATCTGAGTCTGACAGTTGAGCTTAAAATCAAAATTGCTTCAGGATTCGGGCCATTGATCACAC
ACGGTTCAGGGATGGACCTATACAAAACCAACCACAACAATGTGTATTGGCTGACTATCCCGCCAATGAA
GAACCTAGCCTTAGGTGTAATCAACACATTGGAGTGGATACCGAGATTCAAGGTTAGTCCCAACCTCTTC
ACTGTTCCAATCAAGGAAGCAGGCGAGGACTGCCATGCCCCAACATACCTACCTGCGGAGGTGGATGGTG
ATGTCAAACTCAGTTCCAATCTGGTAATTCTACCTGGTCAGGATCTCCAATATGTTTTGGCAACCTACGA
TACTTCCAGGGTTGAACATGCTGTGGTTTATTATGTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTAT
CCTTTTAGGTTGCCTATAAAGGGGGTCCCAATCGAATTACAAGTGGAATGCTTCACATGGGACAAAAAAC
TCTGGTGCCGTCACTTCTGTGTGCTTGCGGACTCAGAATCTGGTGGACATATCACTCACTCTGGGATGGT
GGGCATGGGAGTCAGCTGCACAGTCACTCGGGAAGATGGAACCAATCGCAGATAGGGCTGCCAGTGAACC
GATCACATGATGTCACCCAGACATCAGGCATACCCACTAGTGTGAAATAGACATCAGAATTAAGAAAA

</dna_sequence>
        <protein_sequence>>NP_056923.1 hemagglutinin protein [Measles morbillivirus]
MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEI
HKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKFISDKIKFLNPDREYDFRDLTWCI
NPPERIKLDYDQYCADVAAEELMNALVNSTLLEARATNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYL
SRGYNVSSIVTMTSQGMYGGTYLVGKPNLSSKGSELSQLSMHRVFEVGVIRNPGLGAPVFHMTNYFEQPV
SNDFSNCMVALGELKFAALCHREDSITIPYQGSGKGVSFQLVKLGVWKSPTDMRSWVPLSTDDPVIDRLY
LSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKNQALCENPEWAPLKDNRIPSYGVLSVNLSLT
VELKIKIASGFGPLITHGSGMDLYKTNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPNLFTVPIKEA
GEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIK
GVPIELQVECFTWDKKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles were used to express the hemagglutinin (H) and fusion (F) proteins of measles virus (MV).  When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia [Ref1175:Pan et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1200">
        <gene_name>IFNG</gene_name>
        <strain>Macaca mulatta</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>574282</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>74136365</ncbi_protein_id>
        <gene_locus_tag>EGK_03901</gene_locus_tag>
        <gene_refseq>CM001263</gene_refseq>
        <protein_refseq>NP_001028077</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9544</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>65143979</gene_start>
        <gene_end>65148219</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>interferon-gamma</protein_name>
        <protein_pi>9.92</protein_pi>
        <protein_weight>18339.63</protein_weight>
        <protein_length>165</protein_length>
        <protein_note>Also known as IFN-gamma</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence
ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA
CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG
GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA
GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC
AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT
AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG
GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT
TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT
TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG
CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT
GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA
CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT
CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT
TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT
TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC
TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT
GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC
AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG
AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC
TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG
ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC
TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG
CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA
GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA
CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG
ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG
AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC
ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC
CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG
CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG
CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT
CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA
GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT
CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC
CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA
TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA
ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC
TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT
GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC
ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG
AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC
ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG
TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT
TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT
TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA
TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA
CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT
ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT
GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA
CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA
TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA
ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA
ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT
TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT
CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC
ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC
CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA
TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG
ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA
AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC
AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA</dna_sequence>
        <protein_sequence>>gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta]
MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS
QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM
AELSPAAKIGKRKRSQMFRGRRASQ</protein_sequence>
        <phi_function>Vaximmutor</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene581">
        <gene_name>M matrix protein</gene_name>
        <strain>Measles morbillivirus</strain>
        <vo_id>VO_0011170</vo_id>
        <ncbi_gene_id>1489803</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9626949</ncbi_protein_id>
        <gene_locus_tag>MeVgp3</gene_locus_tag>
        <gene_refseq>AB002686</gene_refseq>
        <protein_refseq>NP_056921</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11234</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>3405</gene_start>
        <gene_end>4871</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>9.25</protein_pi>
        <protein_weight>35032.9</protein_weight>
        <protein_length>335</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001498.1:3405-4871 Measles virus, complete genome
TAGGAGCAAAGTGATTGCCTCCTAAGTTCCACAATGACAGAGATCTACGATTTCGACAAGTCGGCATGGG
ACATCAAAGGGTCGATCGCTCCGATACAACCTACCACCTACAGTGATGGCAGGCTGGTGCCCCAGGTCAG
AGTCATAGATCCTGGTCTAGGTGATAGGAAGGATGAATGCTTTATGTACATGTTTCTGCTGGGGGTTGTT
GAGGACAGCGATCCCCTAGGGCCTCCAATCGGGCGAGCATTCGGGTCCCTGCCCTTAGGTGTTGGTAGAT
CCACAGCAAAACCCGAGGAACTCCTCAAAGAGGCCACTGAGCTTGACATAGTTGTTAGACGTACAGCAGG
GCTCAATGAAAAACTGGTGTTCTACAACAACACCCCACTAACCCTCCTCACACCTTGGAGAAAGGTCCTA
ACAACAGGGAGTGTCTTCAATGCAAACCAAGTGTGCAATGCGGTTAATCTAATACCGCTGGACACCCCGC
AGAGGTTCCGTGTTGTTTATATGAGCATCACCCGTCTTTCGGATAACGGGTATTACACCGTTCCCAGAAG
AATGCTGGAATTCAGATCGGTCAATGCAGTGGCCTTCAACCTGCTAGTGACCCTTAGGATTGACAAGGCG
ATTGGCCCTGGGAAGATCATCGACAATGCAGAGCAACTTCCTGAGGCAACATTTATGGTCCACATCGGGA
ACTTCAGGAGAAAGAAGAGTGAAGTCTACTCTGCCGATTATTGCAAAATGAAAATCGAAAAGATGGGCCT
GGTTTTTGCACTTGGTGGGATAGGGGGCACCAGTCTTCACATTAGAAGCACAGGCAAAATGAGCAAGACT
CTCCATGCACAACTCGGGTTCAAGAAGACCTTATGTTACCCACTGATGGATATCAATGAAGACCTTAATC
GGTTACTCTGGAGGAGCAGATGCAAGATAGTAAGAATCCAGGCAGTTTTGCAGCCATCAGTTCCTCAAGA
ATTCCGCATTTACGACGACGTGATCATAAATGATGACCAAGGACTATTCAAAGTTCTGTAGACCGCAGTG
CCCAGCAATACCCGAAAACGACCCCCCTCATAATGACAGCCAGAAGGCCCGGACAAAAAAGCCCCCTCCA
GAAGACTCCACGGACCAAGCGAGAGGCCAGCCAGCAGCCGACAGCAAGTGTGGACACCAGGCGGCCCAAG
CACAGAACAGCCCCGACACAAGGCCACCACCAGCCATCCCAATCTGCGTCCTCCTCGTGGGACCCCCGAG
GACCAACCCCGAAGGTCGCTCCGAACACAGACCACCAACCGCATCCCCACAGCTCCCGGGAAAGGAACCC
CCAGCAACTGGAAGGCCCCTCCCCCCCTCCCCCAACGCAAGAACCCCACAACCGAACCGCACAAGCGACC
GAGGTGACCCAACCGCAGGCATCCGACTCCTTAGACAGATCCTCTCCCCCCGGCATACTAAACAAAA

</dna_sequence>
        <protein_sequence>>NP_056921.1 matrix protein [Measles morbillivirus]
MTEIYDFDKSAWDIKGSIAPIQPTTYSDGRLVPQVRVIDPGLGDRKDECFMYMFLLGVVEDSDPLGPPIG
RAFGSLPLGVGRSTAKPEELLKEATELDIVVRRTAGLNEKLVFYNNTPLTLLTPWRKVLTTGSVFNANQV
CNAVNLIPLDTPQRFRVVYMSITRLSDNGYYTVPRRMLEFRSVNAVAFNLLVTLRIDKAIGPGKIIDNAE
QLPEATFMVHIGNFRRKKSEVYSADYCKMKIEKMGLVFALGGIGGTSLHIRSTGKMSKTLHAQLGFKKTL
CYPLMDINEDLNRLLWRSRCKIVRIQAVLQPSVPQEFRIYDDVIINDDQGLFKVL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge [Ref1177:Brinckmann et al., 1991].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene579">
        <gene_name>N nucleocapsid protein</gene_name>
        <strain>Measles morbillivirus</strain>
        <vo_id>VO_0011168</vo_id>
        <ncbi_gene_id>1489804</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9626946</ncbi_protein_id>
        <gene_locus_tag>MeVgp1</gene_locus_tag>
        <gene_refseq>AB016162</gene_refseq>
        <protein_refseq>NP_056918</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11234</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>55</gene_start>
        <gene_end>1743</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>4.86</protein_pi>
        <protein_weight>55436.53</protein_weight>
        <protein_length>525</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001498.1:55-1743 Measles virus, complete genome
TAGGATTCAAGATCCTATTATCAGGGACAAGAGCAGGATTAGGGATATCCGAGATGGCCACACTTTTGAG
GAGCTTAGCATTGTTCAAAAGAAACAAGGACAAACCACCCATTACATCAGGATCCGGTGGAGCCATCAGA
GGAATCAAACACATTATTATAGTACCAATTCCTGGAGATTCCTCAATTACCACTCGATCCAGACTACTGG
ACCGGTTGGTCAGGTTAATTGGAAACCCGGATGTGAGCGGGCCCAAACTAACAGGGGCACTAATAGGTAT
ATTATCCTTATTTGTGGAGTCTCCAGGTCAATTGATTCAGAGGATCACCGATGACCCTGACGTTAGCATC
AGGCTGTTAGAGGTTGTTCAGAGTGACCAGTCACAATCTGGCCTTACCTTCGCATCAAGAGGTACCAACA
TGGAGGATGAGGCGGACCAATACTTTTCACATGATGATCCAAGCAGTAGTGATCAATCCAGGTCCGGATG
GTTCGAGAACAAGGAAATCTCAGATATTGAAGTGCAAGACCCTGAGGGATTCAACATGATTCTGGGTACC
ATTCTAGCCCAGATCTGGGTCTTGCTCGCAAAGGCGGTTACGGCCCCAGACACGGCAGCTGATTCGGAGC
TAAGAAGGTGGATAAAGTACACCCAACAAAGAAGGGTAGTTGGTGAATTTAGATTGGAGAGAAAATGGTT
GGATGTGGTGAGGAACAGGATTGCCGAGGACCTCTCTTTACGCCGATTCATGGTGGCTCTAATCCTGGAT
ATCAAGAGGACACCCGGGAACAAACCTAGGATTGCTGAAATGATATGTGACATTGATACATATATCGTAG
AGGCAGGATTAGCCAGTTTTATCCTGACTATTAAGTTTGGGATAGAAACTATGTATCCTGCTCTTGGACT
GCATGAATTTGCTGGTGAGTTATCCACACTTGAGTCCTTGATGAATCTTTACCAGCAAATGGGAGAAACT
GCACCCTACATGGTAATCCTAGAGAACTCAATTCAGAACAAGTTCAGTGCAGGATCATACCCTCTGCTCT
GGAGCTATGCCATGGGAGTAGGAGTGGAACTTGAAAACTCCATGGGAGGTTTGAACTTTGGTCGATCTTA
CTTTGATCCAGCATATTTTAGATTAGGGCAAGAGATGGTGAGGAGGTCAGCTGGAAAGGTCAGTTCCACA
TTGGCATCCGAACTCGGTATCACTGCCGAGGATGCAAGGCTTGTTTCAGAGATTGCAATGCATACTACTG
AGGACAGGATCAGTAGAGCGGTCGGACCCAGACAAGCCCAAGTGTCATTTCTACACGGTGATCAAAGTGA
GAATGAGCTACCAGGATTGGGGGGCAAGGAAGATAGGAGGGTCAAACAGGGTCGGGGAGAAGCCAGGGAG
AGCTACAGAGAAACCGGGTCCAGCAGAGCAAGTGATGCGAGAGCTGCCCATCCTCCAACCAGCATGCCCC
TAGACATTGACACTGCATCGGAGTCAGGCCAAGATCCGCAGGACAGTCGAAGGTCAGCTGACGCCCTGCT
CAGGCTGCAAGCCATGGCAGGAATCTTGGAAGAACAAGGCTCAGACACGGACACCCCTAGGGTATACAAT
GACAGAGATCTTCTAGACTAGGTGCGAGAGGCCGAGGACCAGAACAACATCCGCCTACCCTCCATCATTG
TTATAAAAA

</dna_sequence>
        <protein_sequence>>NP_056918.1 nucleocapsid protein [Measles morbillivirus]
MATLLRSLALFKRNKDKPPITSGSGGAIRGIKHIIIVPIPGDSSITTRSRLLDRLVRLIGNPDVSGPKLT
GALIGILSLFVESPGQLIQRITDDPDVSIRLLEVVQSDQSQSGLTFASRGTNMEDEADQYFSHDDPSSSD
QSRSGWFENKEISDIEVQDPEGFNMILGTILAQIWVLLAKAVTAPDTAADSELRRWIKYTQQRRVVGEFR
LERKWLDVVRNRIAEDLSLRRFMVALILDIKRTPGNKPRIAEMICDIDTYIVEAGLASFILTIKFGIETM
YPALGLHEFAGELSTLESLMNLYQQMGETAPYMVILENSIQNKFSAGSYPLLWSYAMGVGVELENSMGGL
NFGRSYFDPAYFRLGQEMVRRSAGKVSSTLASELGITAEDARLVSEIAMHTTEDRISRAVGPRQAQVSFL
HGDQSENELPGLGGKEDRRVKQGRGEARESYRETGSSRASDARAAHPPTSMPLDIDTASESGQDPQDSRR
SADALLRLQAMAGILEEQGSDTDTPRVYNDRDLLD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVN (Nucleocapsid Protein) -immunized rats survived a MV challenge infection [Ref1177:Brinckmann et al., 1991].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene580">
        <gene_name>P phosphoprotein</gene_name>
        <strain>Measles morbillivirus</strain>
        <vo_id>VO_0011169</vo_id>
        <ncbi_gene_id>1489805</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9626947</ncbi_protein_id>
        <gene_locus_tag>MeVgp2</gene_locus_tag>
        <gene_refseq>AB016162</gene_refseq>
        <protein_refseq>NP_056919</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>11234</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1747</gene_start>
        <gene_end>3401</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>mRNA</protein_name>
        <protein_pi>4.73</protein_pi>
        <protein_weight>52011.09</protein_weight>
        <protein_length>507</protein_length>
        <protein_note>RNA editing; co-transcriptional insertion of a non-template G at nt 2499 of the 'P' protein transcript creates V mRNA</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001498.1:1747-3401 Measles virus, complete genome
TAGGAACCAGGTCCACACAGCCGCCAGCCAACCAACCATCCACTCCCACGACTGGAGCCGATGGCAGAAG
AGCAGGCACGCCATGTCAAAAACGGACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACT
GGCCGTCGAGGAAGCCATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACAGGACCGAGCCACCTGC
AAGGAAGAGGAGGCAGGCAGTTCGGGTCTCAGCAAACCATGCCTCTCAGCAATTGGATCAACTGAAGGCG
GTGCACCTCGCATCCGCGGTCAGGGATCTGGAGAAAGCGATGACGACGCTGAAACTTTGGGAATCCCCTC
AAGAAATCTCCAGGCATCAAGCACTGGGTTACAGTGTTATCATGTTTATGATCACAGCGGTGAAGCGGTT
AAGGGAATCCAAGATGCTGACTCTATCATGGTTCAATCAGGCCTTGATGGTGATAGCACCCTCTCAGGAG
GAGACGATGAATCTGAAAACAGCGATGTGGATATTGGCGAACCTGATACCGAGGGATATGCTATCACTGA
CCGGGGATCTGCTCCCATCTCTATGGGGTTCAGGGCTTCTGATGTTGAAACTGCAGAAGGAGGGGAGATC
CACGAGCTCCTGAAACTCCAATCCAGAGGCAACAACTTTCCGAAGCTTGGGAAAACTCTCAATGTTCCTC
CGCCCCCGAACCCCAGTAGGGCCAGCACTTCCGAGACACCCATTAAAAAGGGCACAGACGCGAGATTGGC
CTCATTTGGAACGGAGATCGCGTCTTTATTGACAGGTGGTGCAACCCAATGTGCTCGAAAGTCACCCTCG
GAACCATCAGGGCCAGGTGCACCTGCGGGGAATGTCCCCGAGTGTGTGAGCAATGCCGCACTGATACAGG
AGTGGACACCCGAATCTGGTACCACAATCTCCCCGAGATCCCAGAATAATGAAGAAGGGGGAGACTATTA
TGATGATGAGCTGTTCTCCGATGTCCAAGACATCAAAACAGCCTTGGCCAAAATACACGAGGATAATCAG
AAGATAATCTCCAAGCTAGAATCATTGCTGTTATTGAAGGGAGAAGTTGAGTCAATTAAGAAGCAGATCA
ACAGGCAAAATATCAGCATATCCACCCTGGAAGGACACCTCTCAAGCATCATGATTGCCATTCCTGGACT
TGGGAAGGATCCCAACGACCCCACTGCAGATGTCGAACTCAATCCCGACCTGAAACCCATCATAGGCAGA
GATTCAGGCCGAGCACTGGCCGAAGTTCTCAAGAAGCCCGTTGCCAGCCGACAACTCCAGGGAATGACTA
ATGGACGGACCAGTTCCAGAGGACAGCTGCTGAAGGAATTTCAACTAAAGCCGATCGGGAAAAAGGTGAG
CTCAGCCGTCGGGTTTGTTCCTGACACCGGCCCTGCATCACGCAGTGTAATCCGCTCCATTATAAAATCC
AGCCGGCTAGAGGAGGATCGGAAGCGTTACCTGATGACTCTCCTTGATGATATCAAAGGAGCCAACGATC
TTGCCAAGTTCCACCAGATGCTGATGAAGATAATAATGAAGTAGCTACAGCTCAACTTACCTGCCAACCC
CATGCCAGTCGACCTAATTAGTACAACCTAAATCCATTATAAAAA

</dna_sequence>
        <protein_sequence>>NP_056919.1 phosphoprotein [Measles morbillivirus]
MAEEQARHVKNGLECIRALKAEPIGSLAVEEAMAAWSEISDNPGQDRATCKEEEAGSSGLSKPCLSAIGS
TEGGAPRIRGQGSGESDDDAETLGIPSRNLQASSTGLQCYHVYDHSGEAVKGIQDADSIMVQSGLDGDST
LSGGDDESENSDVDIGEPDTEGYAITDRGSAPISMGFRASDVETAEGGEIHELLKLQSRGNNFPKLGKTL
NVPPPPNPSRASTSETPIKKGTDARLASFGTEIASLLTGGATQCARKSPSEPSGPGAPAGNVPECVSNAA
LIQEWTPESGTTISPRSQNNEEGGDYYDDELFSDVQDIKTALAKIHEDNQKIISKLESLLLLKGEVESIK
KQINRQNISISTLEGHLSSIMIAIPGLGKDPNDPTADVELNPDLKPIIGRDSGRALAEVLKKPVASRQLQ
GMTNGRTSSRGQLLKEFQLKPIGKKVSSAVGFVPDTGPASRSVIRSIIKSSRLEEDRKRYLMTLLDDIKG
ANDLAKFHQMLMKIIMK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge [Ref1177:Brinckmann et al., 1991].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference1177">
		<reference_name>Brinckmann et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG</authors>
		<title>Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis</title>
		<year>1991</year>
		<volume>72 ( Pt 10)</volume>
		<issue></issue>
		<pages>2491-2500</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1314">
		<reference_name>Drillien et al., 1988</reference_name>
		<reference_type>journal</reference_type>
		<authors>Drillien R, Spehner D, Kirn A, Giraudon P, Buckland R, Wild F, Lecocq JP</authors>
		<title>Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein</title>
		<year>1988</year>
		<volume>85</volume>
		<issue>4</issue>
		<pages>1252-1256</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference722">
		<reference_name>FDA: Attenuvax</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Attenuvax information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm203032.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference791">
		<reference_name>FDA: MMR-II</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: MMR-II</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference796">
		<reference_name>FDA: ProQuad</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: ProQuad Vaccine</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference723">
		<reference_name>Griffin et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Griffin DE, Pan CH, Moss WJ</authors>
		<title>Measles vaccines</title>
		<year>2008</year>
		<volume>13</volume>
		<issue></issue>
		<pages>1352-1370</pages>
		<journal_book_name>Frontiers in bioscience : a journal and virtual library</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference926">
		<reference_name>GSK: Priorix</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>GSK: Priorix Product Information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.gsk.ca/english/docs-pdf/Priorix_PM_20081103_EN.pdf</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference925">
		<reference_name>GSK: Priorix-Tetra</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>GSK: Priorix-Tetra Product Information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.gsk.ca/english/docs-pdf/Priorix-Tetra_PM_20090908_EN.pdf</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2117">
		<reference_name>Martinez et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Martinez X, Brandt C, Saddallah F, Tougne C, Barrios C, Wild F, Dougan G, Lambert PH, Siegrist CA</authors>
		<title>DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life</title>
		<year>1997</year>
		<volume>94</volume>
		<issue>16</issue>
		<pages>8726-8731</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1175">
		<reference_name>Pan et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE</authors>
		<title>A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles</title>
		<year>2010</year>
		<volume>84</volume>
		<issue>8</issue>
		<pages>3798-3807</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1176">
		<reference_name>Spreng et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Spreng S, Gentschev I, Goebel W, Weidinger G, ter Meulen V, Niewiesk S</authors>
		<title>Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis</title>
		<year>2000</year>
		<volume>2</volume>
		<issue>14</issue>
		<pages>1687-1692</pages>
		<journal_book_name>Microbes and infection / Institut Pasteur</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1545">
		<reference_name>Wiki: Measles</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Wiki: Measles</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://en.wikipedia.org/wiki/Measles</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference724">
		<reference_name>Yanagi et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yanagi Y, Takeda M, Ohno S</authors>
		<title>Measles virus: cellular receptors, tropism and pathogenesis</title>
		<year>2006</year>
		<volume>87</volume>
		<issue>Pt 10</issue>
		<pages>2767-2779</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


